03 December, 2025 in Investor Relations Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer’s Disease Program
02 December, 2025 in Investor Relations Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on December 4
18 November, 2025 in Investor Relations Nexalin’s 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity
13 November, 2025 in Investor Relations Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel
05 November, 2025 in Investor Relations Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia
30 October, 2025 in Investor Relations Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel
21 October, 2025 in Investor Relations Nexalin’s DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer’s and Dementia Across Three Peer-Reviewed Studies
13 October, 2025 in Investor Relations Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer’s and Traumatic Brain Injury Programs
10 October, 2025 in Investor Relations Nexalin Technology Announces Attendance at the 2025 Maxim Growth Summit
08 October, 2025 in Investor Relations Nexalin Technology Announces Additional Positive Clinical Results in Alzheimer’s Disease with Gen-2 SYNC Neurostimulation Device
